Fluorescein Sodium/Proparacaine Hydrochloride
Pronouncation: (FLURE-eh-seen SO-dee-uhm/pro-PAR-ah-cane HIGH-droe-KLOR-ide)
Class: Local anesthetic
Trade Names:
Fluoracaine
- Solution 0.5% proparacaine hydrochloride and 0.25% fluorescein sodium
Mechanism of Action
Pharmacology
Fluorescein
Diagnostic aid (corneal trauma indicator)
Proparacaine
Stabilizes neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.
Indications and Usage
Procedures requiring a disclosing agent in combination with an anesthetic agent (eg, tonometry, gonioscopy, removal of corneal foreign bodies and other short corneal or conjunctival procedures).
Contraindications
Known hypersensitivity to any component of the product.
Dosage and Administration
Removal of Foreign Bodies and Sutures and for Tonometry
Adults
Topical Single instillation of 1 to 2 drops in each eye before operating.
Deep Ophthalmic Anesthesia
Adults
Topical Instill 1 drop in each eye every 5 to 10 min for 5 to 7 doses.
General Advice
- For ophthalmic use only. Not for use in the ears or on the skin.
Storage/Stability
Store solution in refrigerator (36° to 46°F). Keep bottle tightly capped and protect from light.
Drug Interactions
None well documented.
Laboratory Test Interactions
None well documented.
Adverse Reactions
CNS
Stimulation followed by depression.
EENT
Temporary stinging; burning; conjunctival redness; immediate-type hyperallergic corneal reaction (with acute, intense, and diffuse epithelial keratitis, gray, ground glass appearance, sloughing of large areas of necrotic epithelium corneal filaments and sometimes, iritis with descemetitis).
Dermatologic
Allergic contact dermatitis (with drying and fissuring of the fingertips).
Precautions
Pregnancy
Category C .
Lactation
Undetermined.
Children
Safety and efficacy not established.
Special Risk Patients
Use with caution in patients with known allergies, cardiac disease, or hyperthyroidism.
Prolonged use
Not recommended; may cause permanent corneal opacification with visual loss and delay wound healing.
Patient Information
- Advise patient that medication will be prepared and administered by a health care provider in a medical setting to obtain short-term anesthesia of the eye(s).
- Caution patient to avoid rubbing or touching the eye(s) until the anesthesia has worn off.
- Inform patient that temporary blurred vision, stinging or burning, or redness of the eye are the most common adverse reactions and to contact their health care provider if they occur and are bothersome.
Recent Drug Updates at Web Drug List
Atuss HD
Bleph-10 Drops
Calcijex
Calcitonin (Salmon)
Cataflam
DDAVP Rhinal Tube
Dimetapp Decongestant
Lactaid Ultra Chewable Tablets
Marcaine Parenteral-Local
Neutrogena Moisture Untinted & with Sheer Tint Topical
|